.png)
.png)
Послать статью по эл. почте 
Иммунологические тесты со специфичными для Mycobacterium tuberculosis белками ESAT-6 и CFP-10
https://doi.org/10.21292/2075-1230-2014-0-1-54-56
Аннотация
Иммунологические тесты со специфичными для Mycobacterium tuberculosis белками ESAT-6 и CFP-10
Об авторе
Л. В. Слогоцкаядоктор медицинских наук, профессор кафедры фтизиатрии;
заведующая научно-клиническим отделом
Список литературы
1. Литература
2. Борисов С. Е., Лукина Г. В., Слогоцкая Л. В. и др. Скрининг и мониторинг туберкулёзной инфекции у ревматологических больных, получающих генно-инженерные биологические препараты // Туб. – 2011. – № 6. – С. 42-50.
3. Долженко Е. Н. Использование аллергена туберкулезного рекомбинантного (Диаскинтеста) в выявлении активного туберкулеза у детей // Туб. – 2013. – № 6. – C. 28-29.
4. Корнева Н. В., Старшинова А. А., Овчинникова Ю. Э. и др. Сравнение результатов пробы Манту с 2 ТЕ и Диаскинтеста при различных проявлениях туберкулезной инфекции // Туб. – 2013. – № 6. – C. 49-50.
5. Овсянкина Е. С., Губкина М. Ф., Ершова Н. Г. и др. Опыт применения нового кожного теста (Диаскинтеста®) для диагностики туберкулеза органов дыхания у детей и подростков в туберкулезном отделении // Туб. – № 1. – 2010. – С. 16-19.
6. Слогоцкая Л. В., Иванова Д. А., Кочетков Я. А. и др. Сравнительные результаты кожного теста с препаратом, содержащим рекомбинантный белок CFP-10-ESAT-6 и лабораторного теста QuantiFERON - GIT // Туб. – 2012. – № 10 – С. 27-33
7. Слогоцкая Л. В., Кочетков Я. А., Сенчихина О. Ю. и др. Динамика кожной пробы (Диаскинтест) у детей при оценке активности туберкулезной инфекции // Туб. – 2011. – № 2 – С. 59-63.
8. Слогоцкая Л. В., Сенчихина О. Ю., Богородская Е. М. Чувствительность теста с аллергеном туберкулезным рекомбинантным, содержащим белок ESAT6-CFP10 у впервые выявленных больных туберкулезом детей и подростков в г. Москве // Туб. и соц. знач. заболевания. – 2013. – № 1. – С. 37-44.
9. Andersen P., Doherty T., Pai M. et al. The prognosis of latent tuberculosis: can disease be predicted? // Trends. Mol. Med. – 2007. – Vol. 13, № 5. – P. 175-182.
10. Andersen Р. Vaccine strategies against latent tuberculosis infection // Trends Microbiol. – 2006. – Vol. 10. – P. 1016.
11. Bakir M., Millington K. A., Soysal A. et al. Prognostic value of a T-cell-based, interferon-γ biomarker in children with tuberculosis contact // Ann. Intern. Med. – 2008. – Vol. 149. – Р. 777-787.
12. Brändli O., Desgrandchamps D., Gabathuler U. et al. Manual of Tuberculosis. Bern, Swiss Lung League, 2007. www.lung.ch
13. Diel R., Loddenkemper R., Meywald-Walter K. et al. Predictive value of a whole-blood IFN-γ-assay for the development of active TB disease// Am J. Respir. Crit. Care Med. –2008. – Vol. 177. – Р. 1164-1170.
14. Diel R., Nienhaus A., Schaberg T. Cost-effectiveness of isoniazid chemoprevention in close contacts // Eur. Respir. J. – 2005. – Vol. 26. – Р. 465-473.
15. Dietrich J., Aagaard C., Leah R. et al. Exchanging ESAT6 with TB10.4 in an Ag85B fusion molecule-based tuberculosis subunit vaccine: efficient protection and ESAT6-based sensitive monitoring of vaccine efficacy // J. Immunol. – 2005. – Vol. 174. – P. 6332-6339.
16. Doherty T., Demissie A., Olobo J. et al. Immune responses to the Mycobacterium tuberculosis-specific antigen ESAT-6 signal subclinical infection among contacts of tuberculosis patients // J. Clin. Microbiol. – 2002. – Vol. 40. – Р. 704-706.
17. Doherty T., Wallis R., Zumla A. Biomarkers of disease activity, cure, and relapse in tuberculosis // Clin. Chest. Med. – 2009. – Vol. 30, № 4. – P. 783-796.
18. Dosanjh D., Hinks T., Innes J. et al. Improved diagnostic evaluation of suspected tuberculosis // Ann. Intern. Med. – 2008. – Vol. 148. – Р. 325-336.
19. Goletti D., Stefania C., Butera O. et al. Accuracy of immunodiagnostic tests for active tuberculosis using single and combined results: a multicenter TBNET Study//PLoS One. – 2008. – Vol. 3: e3417.
20. Guidelines for the investigation of contacts of persons with infectious tuberculosis. Recommendations from the National Tuberculosis Controllers Association and CDC // MMWR Recomm. Rep. – 2005. – Vol. 54. – Р. 1-47.
21. Guinn K., Hickey M., Mathur S. et al. Individual RD1-region genes are required for export of ESAT-6/CFP-10 and for virulence of Mycobacterium tuberculosis // Mol. Microbiol. – 2004. – Vol. 51. – P. 359-370.
22. Harboe M., Oettinger T., Wiker H. et al. Evidence for occurrence of the ESAT-6 protein in Mycobacterium tuberculosis and virulent Mycobacterium bovis and for its absence in Mycobacterium bovis BCG // Infect. Immun. – 1996. – Vol. 64. – P. 16-22.
23. Lalvani A., Millington K. A. T cell-based diagnosis of childhood tuberculosis infection // Curr. Opin. Infect. Dis. – 2007. – Vol. 20. – Р. 264-271.
24. Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy // Chest. – 2007. – Vol. 131. – Р. 1898-1906.
25. Lienhardt C., Fielding K., Hane A. et al. Evaluation of the prognostic value of IFN-γ release assay and tuberculin skin test in household contacts of infectious tuberculosis cases in senegal // PLoS ONE. – 2010. – 5(5): e10508. doi:10.1371/journal.pone.0010508.
26. Mack U., Migliori G., Sester M. et al. LTBI: latent tuberculosis infection or lasting immune responses to Mycobacterium tuberculosis? A TBNET consensus statement // Eur. Respir. J. – 2009. – Vol. 33. – P. 956-973.
27. Mahairas G., Sabo P., Hickey M. et al. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis //J. Bacteriol. – 1996. – Vol. 178. – P. 1274-1282.
28. Mazurek G., Jereb J., Lobue P. et al. Guidelines for using the QuantiFERON-TB Gold test for detecting Mycobacterium tuberculosis infection, United States // MMWR Recomm Rep. – 2005. – Vol. 54. – Р. 49-55.
29. Mazurek G., Weis S., Moonan P. et al. Prospective comparison of the tuberculin skin test and two whole-blood interferon-gamma release assays in persons with suspected tuberculosis // Clin. Infect. Dis. – 2007. – Vol. 45. – P. 837-845.
30. Mori T., Sakatani M., Yamagishi F. et al. Specific detection of tuberculosis infection: an interferon-c-based assay using new antigens // Am. J. Respir. Crit. Care Med. – 2004. – Vol. 170. – Р. 59-64.
31. National Institute for Health and Clinical Excellence. Tuberculosis: Clinical Diagnosis and Management of Tuberculosis, and Measures for its Prevention and Control. London, National Institute for Health and Clinical Excellence, 2006. www.nice.org.uk.
32. Pai M., Menzies D. Interferon-γ release assays: what is their role in the diagnosis of active tuberculosis? // Clin. Infect. Dis. – 2007. – Vol. 44. – Р. 74-77.
33. Pai M., Kalantri S., Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis: part I. Latent tuberculosis // Expert. Rev. Mol. Diagn. – 2006. – Vol. 6. – Р. 413-422.
34. Pai M., Zwerling A., Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update //Ann. Intern. Med. ― 2008. – Vol. 149, № 3. – P. 177-184.
35. Richeldi L., Ewer K., Losi M. et al. Early diagnosis of subclinical multidrug-resistant tuberculosis // Ann. Intern. Med. – 2004. – Vol. 140. – Р. 709-713.
36. Shi L., North R., Gennaro M. Effect of growth state on transcription levels of genes encoding major secreted antigens of Mycobacterium tuberculosis in the mouse lung // Infect. Immun. – 2004. – Vol. 72, № 4. – P. 2420-2424.
37. Slogotskaya L., Bogorodskaya E., Litvinov V. et al. Prevalence of Tuberculosis Infection Estimated By Skin Testing With Recombinant Protein CFP10-ESAT6 Among Hospital Workers In //EAACI-WAO World Allergy and Asthma Congress 2013.-22-26 June 2013 Milan, Italy//www.postersessiononline.com/173580348_eu/congresos/EAACI2013/aula/-P_1158_EAACI2013.pdf
38. Slogotskaya L., Litvinov V., Seltsovsky P. et al. New skin test DIASKINTEST® (recombinant protein CFP10-ESAT6) in children for TB infection diagnosis //Allergy. Eur. J. Allerg. Clin. Immunol. – Vol. 65, suppl. S. 92 DOI: 10.1111/j.1398-9995.2010.02396х.
39. Slogotskaya L., Litvinov V., Seltsovsky P. et al. Sensitivity and specificity of new skin test - Diaskintest (recombinant protein CFP10-ESAT6) in patients with tuberculosis and individuals with non-tuberculous pulmonary diseases. //European Academy of Allergy and Clinical Immunology (EAACI) 30th Annual Congress, Istanbul, Turkey, June 11-15, 2011 // DOI: 10.3252/pso.eu.30eaaci.2011
40. Slogotskaya L., Ovsyankina E., Litvinov V. et al. Effectiveness of tuberculosis detection among adolescent student contacts with a new, specific skin test diaskintest which represents recombinant protein CFP10-ESAT6 //European Academy of Allergy and Clinical Immunology (EAACI) 30th Annual Congress, Istanbul June 11-15, 2011// DOI: 10.3252/pso.eu.30eaaci.2011
41. The National Collaborating Centre for Chronic Conditions. Tuberculosis. Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. London, Royal College of Physicians, 2006.
42. Vordermeier H., Chambers M., Cockle P. et al. Correlation of ESAT-6-specific gamma interferon production with pathology in cattle following Mycobacterium bovis BCG vaccination against experimental bovine tuberculosis // Infect. Immun. – 2002. – Vol. 70. – P. 3026-3032.
43. Weldingh K., Andersen P. ESAT-6/CFP10 Skin test predicts disease in M. tuberculosis-infected guinea pigs // PLoS ONE. – 2008. – Vol. 3, № 4. – P. 1978.
Дополнительные файлы
Для цитирования: Слогоцкая Л.В. Иммунологические тесты со специфичными для Mycobacterium tuberculosis белками ESAT-6 и CFP-10. Туберкулез и болезни легких. 2014;(1):54-56. https://doi.org/10.21292/2075-1230-2014-0-1-54-56
For citation: Слогоцкая Л.В. IMMUNOLOGICAL TESTS USING MYCOBACTERIUM TUBERCULOSISSPECIFIC PROTEINS ESAT-6 AND CFP-10. Tuberculosis and Lung Diseases. 2014;(1):54-56. (In Russ.) https://doi.org/10.21292/2075-1230-2014-0-1-54-56
Обратные ссылки
- Обратные ссылки не определены.
